Karyopharm Therapeutics Inc. Quarterly Operating Income (Loss) in USD from Q1 2012 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: Karyopharm Therapeutics Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2012 to Q3 2024.
Karyopharm Therapeutics Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$26.3M, a 15.9% increase year-over-year.
Karyopharm Therapeutics Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$126M, a 0.29% decline year-over-year.
Karyopharm Therapeutics Inc. annual Operating Income (Loss) for 2023 was -$130M, a 8.9% increase from 2022.
Karyopharm Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$142M, a 44.7% decline from 2021.
Karyopharm Therapeutics Inc. annual Operating Income (Loss) for 2021 was -$98.3M, a 42.8% increase from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024	-$126M	-$26.3M	+$4.98M	+15.9%	Jul 1, 2024	Sep 30, 2024	10-Q	2024-11-05
Q2 2024	-$131M	-$28.1M	+$1.45M	+4.91%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-06
Q1 2024	-$132M	-$33.8M	-$2.86M	-9.26%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-08
Q4 2023	-$130M	-$37.8M	-$3.94M	-11.6%	Oct 1, 2023	Dec 31, 2023	10-K	2024-02-29
Q3 2023	-$126M	-$31.3M	-$421K	-1.37%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-11-05
Q2 2023	-$125M	-$29.6M	+$13.3M	+31.1%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-06
Q1 2023	-$139M	-$30.9M	+$3.69M	+10.7%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-08
Q4 2022	-$142M	-$33.9M	-$80.8M	-172%	Oct 1, 2022	Dec 31, 2022	10-K	2024-02-29
Q3 2022	-$61.4M	-$30.8M	+$13M	+29.6%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-02
Q2 2022	-$74.3M	-$42.9M	+$6.14M	+12.5%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-02
Q1 2022	-$80.5M	-$34.6M	+$17.8M	+34%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-04
Q4 2021	-$98.3M	$47M	+$84M		Oct 1, 2021	Dec 31, 2021	10-K	2024-02-29
Q3 2021	-$182M	-$43.8M	+$3.3M	+7%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-03
Q2 2021	-$186M	-$49M	-$8.73M	-21.7%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-04
Q1 2021	-$177M	-$52.4M	-$5.02M	-10.6%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-05
Q4 2020	-$172M	-$37.1M	+$6.2M	+14.3%	Oct 1, 2020	Dec 31, 2020	10-K	2023-02-17
Q3 2020	-$178M	-$47.1M	-$7.71M	-19.6%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-03
Q2 2020	-$170M	-$40.3M	+$1.37M	+3.28%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-05
Q1 2020	-$172M	-$47.4M	+$17.6M	+27.1%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-04
Q4 2019	-$189M	-$43.3M	+$14.2M	+24.7%	Oct 1, 2019	Dec 31, 2019	10-K	2022-03-01
Q3 2019	-$203M	-$39.4M	+$9.75M	+19.8%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-02
Q2 2019	-$213M	-$41.7M	-$7.35M	-21.4%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-04
Q1 2019	-$206M	-$64.9M	-$26M	-66.7%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-05
Q4 2018	-$180M	-$57.5M	-$18M	-45.6%	Oct 1, 2018	Dec 31, 2018	10-K	2019-02-28
Q3 2018	-$162M	-$49.2M	-$18.1M	-58.3%	Jul 1, 2018	Sep 30, 2018	10-Q	2019-11-04
Q2 2018	-$144M	-$34.3M	-$4.58M	-15.4%	Apr 1, 2018	Jun 30, 2018	10-Q	2019-08-07
Q1 2018	-$139M	-$38.9M	-$8.66M	-28.6%	Jan 1, 2018	Mar 31, 2018	10-Q	2019-05-09
Q4 2017	-$131M	-$39.5M	-$12.3M	-45.2%	Oct 1, 2017	Dec 31, 2017	10-K	2019-02-28
Q3 2017	-$118M	-$31.1M	-$5.31M	-20.6%	Jul 1, 2017	Sep 30, 2017	10-K	2019-02-28
Q2 2017	-$113M	-$29.8M	+$724K	+2.38%	Apr 1, 2017	Jun 30, 2017	10-K	2019-02-28
Q1 2017	-$114M	-$30.3M	-$2.93M	-10.7%	Jan 1, 2017	Mar 31, 2017	10-K	2019-02-28
Q4 2016	-$111M	-$27.2M	+$2.14M	+7.3%	Oct 1, 2016	Dec 31, 2016	10-K	2018-03-15
Q3 2016	-$113M	-$25.7M	+$4.87M	+15.9%	Jul 1, 2016	Sep 30, 2016	10-K	2018-03-15
Q2 2016	-$118M	-$30.5M	+$2.54M	+7.69%	Apr 1, 2016	Jun 30, 2016	10-K	2018-03-15
Q1 2016	-$120M	-$27.3M	-$1.2M	-4.59%	Jan 1, 2016	Mar 31, 2016	10-K	2018-03-15
Q4 2015	-$119M	-$29.3M	-$3.36M	-13%	Oct 1, 2015	Dec 31, 2015	10-K	2017-03-16
Q3 2015	-$116M	-$30.6M	-$10.9M	-55%	Jul 1, 2015	Sep 30, 2015	10-K	2017-03-16
Q2 2015	-$105M	-$33M	-$16.6M	-101%	Apr 1, 2015	Jun 30, 2015	10-K	2017-03-16
Q1 2015	-$88.3M	-$26.2M	-$12.4M	-90.7%	Jan 1, 2015	Mar 31, 2015	10-K	2017-03-16
Q4 2014	-$75.8M	-$25.9M	-$13.8M	-114%	Oct 1, 2014	Dec 31, 2014	10-K	2016-03-15
Q3 2014	-$62.1M	-$19.7M	-$10.4M	-112%	Jul 1, 2014	Sep 30, 2014	10-K	2016-03-15
Q2 2014	-$51.6M	-$16.4M	-$9.58M	-139%	Apr 1, 2014	Jun 30, 2014	10-K	2016-03-15
Q1 2014	-$42.1M	-$13.7M	-$8.1M	-144%	Jan 1, 2014	Mar 31, 2014	10-K	2016-03-15
Q4 2013	-$34M	-$12.1M	-$7.91M	-187%	Oct 1, 2013	Dec 31, 2013	10-K	2015-03-13
Q3 2013	-$26M	-$9.32M	-$5.69M	-156%	Jul 1, 2013	Sep 30, 2013	10-K	2015-03-13
Q2 2013	-$20.4M	-$6.87M	-$2.84M	-70.3%	Apr 1, 2013	Jun 30, 2013	10-K	2015-03-13
Q1 2013	-$17.5M	-$5.61M	-$1.63M	-40.9%	Jan 1, 2013	Mar 31, 2013	10-K	2015-03-13
Q4 2012	-$15.9M	-$4.24M			Oct 1, 2012	Dec 31, 2012	10-K	2014-03-21
Q3 2012		-$3.64M			Jul 1, 2012	Sep 30, 2012	10-K	2014-03-21
Q2 2012		-$4.03M			Apr 1, 2012	Jun 30, 2012	10-K	2014-03-21
Q1 2012		-$3.98M			Jan 1, 2012	Mar 31, 2012	10-K	2014-03-21

* An asterisk sign (*) next to the value indicates that the value is likely invalid.